New introduction supports industry shortage of high-yield filling service providers CARLSBAD, CA – Argonaut Manufacturing Services, a premier contract development and manufacturing organization (CDMO) for biopharma, has announced the recent
As point-of-care (POC) diagnostics and high throughput sequencing expand in popularity, the need for room temperature-stable products grows. POC diagnostics need to be capable of ambient storage in order to
With API (active pharmaceutical ingredient) values continuing to climb as production scales conversely drop, it is time to rethink our aseptic filling processes to minimize API loss. The rise in
Mark O’Donnell Joins Argonaut Manufacturing Services Board Carlsbad, CA, Nov 05, 2019 – Argonaut Manufacturing Services announced today that Mark O’Donnell has been appointed to the company’s Board of Directors.
Every journey to contract manufacturing is unique. Some biotech companies know, at the start, they want to work with a contract manufacturing organization (CMO), while others choose to engage a
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_size=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=””
Scale-up and automation in life science manufacturing is challenging. When picturing a manufacturing line, you likely conjure up images of automated multi-function equipment or deft robotic arms. However, for the
Life science companies, from reagents to diagnostics, rely on cold chain shipping. A vital component in the chain is the ubiquitous polystyrene cooler. Yet, with restaurant polystyrene bans growing in
Being a biotech startup is exciting. Your company is young, energetic, and full of potential. However, your company is likely lacking in two key areas: cash and time. Startups have
Blockbuster drugs and one-size-fits-all treatments now share portfolio space with highly targeted therapies for smaller patient populations. This new era is an opportunity for savvy companies to create greater value,